WO2018100017A1 - Method and system for treating biological samples - Google Patents
Method and system for treating biological samples Download PDFInfo
- Publication number
- WO2018100017A1 WO2018100017A1 PCT/EP2017/080894 EP2017080894W WO2018100017A1 WO 2018100017 A1 WO2018100017 A1 WO 2018100017A1 EP 2017080894 W EP2017080894 W EP 2017080894W WO 2018100017 A1 WO2018100017 A1 WO 2018100017A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fixed cell
- electromagnetic radiation
- cell sample
- sample
- retrieval agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 239000012472 biological sample Substances 0.000 title description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 65
- 239000000758 substrate Substances 0.000 claims description 36
- 230000005670 electromagnetic radiation Effects 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 16
- 238000002604 ultrasonography Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003196 chaotropic effect Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000012038 nucleophile Substances 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 41
- 102000036639 antigens Human genes 0.000 abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 abstract description 11
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 239000000523 sample Substances 0.000 description 89
- 230000005855 radiation Effects 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 59
- 239000000427 antigen Substances 0.000 description 37
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 241001510071 Pyrrhocoridae Species 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- -1 polysaccharides) Chemical class 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000007979 citrate buffer Substances 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- 210000002741 palatine tonsil Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 5
- 239000000834 fixative Substances 0.000 description 5
- 150000007517 lewis acids Chemical class 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 3
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CVRXLMUYFMERMJ-UHFFFAOYSA-N N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CCN(CC=1N=CC=CC=1)CC1=CC=CC=N1 CVRXLMUYFMERMJ-UHFFFAOYSA-N 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- ZWEVPYNPHSPIFU-AUGHYPCGSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-n-[3-[3-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]propyl-[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenan Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@@H](O)C1 ZWEVPYNPHSPIFU-AUGHYPCGSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- NCDVKGXYZVVEKW-UHFFFAOYSA-N 1-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid Chemical compound OS(=O)(=O)C(C)NC(CO)(CO)CO NCDVKGXYZVVEKW-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- SIHSSUWJKIEVGQ-UHFFFAOYSA-N 14-methyl-1-(14-methylpentadecoxy)pentadecane Chemical compound CC(C)CCCCCCCCCCCCCOCCCCCCCCCCCCCC(C)C SIHSSUWJKIEVGQ-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical class CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- RDIMQHBOTMWMJA-UHFFFAOYSA-N 4-amino-3-hydrazinyl-1h-1,2,4-triazole-5-thione Chemical compound NNC1=NNC(=S)N1N RDIMQHBOTMWMJA-UHFFFAOYSA-N 0.000 description 1
- BOMWLYNXTGNSSE-UHFFFAOYSA-N 5,5'-dimethyl-BAPTA Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C)C=2)N(CC(O)=O)CC(O)=O)=C1 BOMWLYNXTGNSSE-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 241000243818 Annelida Species 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000289419 Metatheria Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229940123742 Peroxidase inhibitor Drugs 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- GNJXVFXIDHCCKR-UHFFFAOYSA-N acetyloxymethyl 2-[[2-(acetyloxymethoxy)-2-oxoethyl]-[2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]ethoxy]ethoxy]ethyl]amino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)CCOCCOCCN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O GNJXVFXIDHCCKR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 229950004243 cacodylic acid Drugs 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OJSUWTDDXLCUFR-YVKIRAPASA-N deoxy-bigchap Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@H](O)C1 OJSUWTDDXLCUFR-YVKIRAPASA-N 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- VDEGQTCMQUFPFH-UHFFFAOYSA-N hydroxy-dimethyl-arsine Natural products C[As](C)O VDEGQTCMQUFPFH-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 239000003996 polyglycerol polyricinoleate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/44—Sample treatment involving radiation, e.g. heat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
Definitions
- the present disclosure relates to a method and system for unmasking protein antigens and nucleic acid targets from fixed biological samples, and more particularly, to a method and system for unmasking antigens and targets in fixed biological samples using ultraviolet light.
- Fixation of tissue and cell samples is used to help ensure that the morphology of the sample and the spatial distribution of biomolecules is preserved and thus used for the basis of a diagnosis by a pathologist.
- the presence of particular proteins and/or nucleic acid sequences can be used to further characterize a disease state and, in some instances, is used by an oncologist to direct therapy of the disease.
- fixation can also interfere with the detection of proteins and nucleic acids in a sample.
- an unmasking step also known as “antigen retrieval” or “target retrieval” for IHC and ISH, respectively
- protein antigens or nucleic acid targets accessible to detection reagents such as antibodies or probes.
- NBF neutral- buffered formalin
- the present disclosure provides methods and systems that facilitate the detection of protein and/or nucleic acid targets in a sample.
- the present disclosure is a method for preparing a fixed cell sample for analysis, the method including contacting the sample with a retrieval agent and exposing the fixed cell sample to electromagnetic radiation, the electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm (UV radiation). In some embodiments, the electromagnetic radiation has a wavelength of between about 200 nm and about 400 nm. In some embodiments, the electromagnetic radiation has a wavelength of between about 250 nm and about 400nm.
- the electromagnetic radiation includes one or more of UVA radiation (having a wavelength ranging from about 315nm to about 400 nm), UVB radiation (having a wavelength ranging from about 280nm to about 315 nm), and UVC radiation (having a wavelength ranging from about lOOnm to about280 nm).
- the retrieval agent is an antigen retrieval agent which includes one or more of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
- the antigen retrieval agent includes at least two of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
- the antigen retrieval agent includes at least three of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
- the antigen retrieval agent includes a buffer (e.g. TRIS) and has a pH ranging from about 7 to about 9.
- the method includes exposing the sample to one or more of heat, microwaves and ultrasound.
- the sample is heated to between about 60 C and about 150 C.
- when the sample is heating it can be held under pressure to minimize evaporation of the antigen retrieval agent or mitigate or prevent the boiling of the antigen retrieval agent.
- an automated system for treating a fixed cell sample mounted on a substrate including a substrate holder configured to hold the substrate, and a reagent dispenser configured to dispense a retrieval agent, e.g. an antigen retrieval agent, onto the fixed cell sample.
- the system includes an electromagnetic radiation source configured to direct UV electromagnetic radiation toward the fixed cell sample.
- UV electromagnetic radiation directed toward the fixed cell sample has wavelength of between about 200 nm and about 400 nm.
- the system also includes a controller configured to control the dispenser and the electromagnetic radiation source to deliver the retrieval agent and direct the electromagnetic radiation (at a suitable wavelength or range of wavelengths) to the fixed cell sample mounted on the substrate.
- the controller directs the operation of the dispenser and/or radiation source to operate according to a predetermined sequence and/or for a predetermined amount of time. In some embodiments, the controller optionally enables the direction of electromagnetic radiation toward the sample at a predetermined intensity or at a predetermined radiation flux.
- the substrate holder includes a heating element. In some embodiments, the substrate holder is enclosed in a pressurizable chamber.
- the system includes a source of microwave radiation that can be used to heat the sample and/or the retrieval agent. In some embodiments, the microwave radiation employed has a wavelength ranging from between about 7.5 cm to about 15 cm. In some embodiments, the substrate is glass. In some embodiments, the substrate is a microscope slide.
- an apparatus for the treatment of a fixed cell sample including a pressurizable chamber, a removable rack for mounting one or more substrates holding one or more fixed cell samples, and a UV light source configured to operate within the pressurizable chamber and direct UV light onto the one or more fixed cell samples.
- a central UV light source is surrounded by a sample rack that fits around the periphery of the pressurizable chamber.
- FIG. 1 is a set of images showing the UV reactor apparatus used to expose the tissue samples shown in FIGS. 1 and 2 to UV light, where panel A is the outside of the UV reactor apparatus, panel B is a view from the top of the reactor showing the UV light sources arranged around the periphery, and panel C shows the tray in which slides were held at the bottom of the reactor apparatus.
- FIG. 2 is set of micrographs illustrating the effect of ultraviolet treatment according to a disclosed method on FFPET tonsil tissue samples stained for the protein BCL-2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
- panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution
- panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer
- panel C shows the results for 1 hour of UV light exposure
- panel D shows the results for 30 minutes of UV light exposure
- panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
- FIG. 3 is a set of micrographs at a higher magnification that correspond to the micrographs of FIG. 2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
- FIG. 4 is a schematic of an embodiment of the disclosed automated system for treating biological samples on microscope slides.
- FIG. 5 is a top-view schematic showing an embodiment of the disclosed apparatus for treatment of a fixed cell sample according to a disclosed method.
- the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
- At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- a method involving steps a, b, and c means that the method includes at least steps a, b, and c.
- steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary unless a particular order is clearly indicated by the context.
- the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
- the term “about” generally refers to a range of numerical values (e.g., +/— 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.
- the term “substantially” means the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. In some embodiments, “substantially” means within about 20%. In some embodiments, “substantially” means within about 15%. In some embodiments, “substantially” means within about 10%. In some embodiments,
- antigen refers to a compound, composition, or substance that may be specifically bound by the products of specific humoral or cellular immunity, such as an antibody molecule or T-cell receptor.
- Antigens can be any type of molecule including, for example, haptens, simple intermediary metabolites, sugars (e.g., oligosaccharides), lipids, and hormones as well as macromolecules such as complex carbohydrates (e.g., polysaccharides), phospholipids, nucleic acids and proteins.
- biological sample refers to any sample including a biomolecule (such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof) that is obtained from any organism including viruses.
- a biomolecule such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof
- Other examples of organisms include mammals (such as humans; veterinary animals like cats, dogs, horses, cattle, and swine; and laboratory animals like mice, rats and primates), insects, annelids, arachnids, marsupials, reptiles, amphibians, bacteria, and fungi.
- Biological samples include tissue samples (such as tissue sections and needle biopsies of tissue), cell samples (such as cytological smears such as Pap smears or blood smears or samples of cells obtained by microdissection), or cell fractions, fragments or organelles (such as obtained by lysing cells and separating their components by centrifugation or otherwise).
- tissue samples such as tissue sections and needle biopsies of tissue
- cell samples such as cytological smears such as Pap smears or blood smears or samples of cells obtained by microdissection
- cell fractions, fragments or organelles such as obtained by lysing cells and separating their components by centrifugation or otherwise.
- biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (for example, obtained by a surgical biopsy or a needle biopsy), nipple aspirates, cerumen, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.
- the term "biological sample” as used herein refers to a sample (such as a homogenized or liquefied sample) prepared from a tumor or a portion thereof obtained from a subject.
- the term "cell sample” refers to a biological sample comprising cells or a morphological portion thereof, which cells can be individual cells or can be arranged together in a tissue structure.
- the cell sample is a collection of cells (such as blood or cervical cells) placed onto a microscope slide.
- the cell sample is a frozen tissue section placed on a microscope slide.
- the cell sample is a formalin-fixed paraffin-embedded tissue sample (FFPET sample), prepared by first fixing a collection of cells or a piece of tissue using formalin, which is then processed using know techniques to dehydrate the sample, clear the sample and impregnate the sample in a block of paraffin (or other materials) such that it can be sliced into thin sections that are placed onto a microscope slide for treatment and analysis.
- FLPET sample formalin-fixed paraffin-embedded tissue sample
- the term "fixed cell sample” refers to a biological sample that has been treated to help preserve the morphological and/or biochemical features of the cells as they existed before the biological sample was obtained from the organism or alternatively before the sample was obtained from a culture of material originally obtained from a biological sample (e.g.
- a fixed cell sample can, for example, be prepared by contacting the sample with an aldehyde fixative such as formaldehyde or glutaraldehyde.
- a fixed cell sample can be prepared by contacting the sample with an alcohol-based fixative such as one including methanol, ethanol or acetic acid.
- a fixed cell sample can be prepared by contacting the sample with an oxidizing agent such as osmium tetraoxide or potassium permanganate, or a fixed cell sample can be prepared using a metallic based fixative such as mercuric chloride or picric acid.
- a fixed cell sample is prepared by contacting a biological sample comprising cells with a neutral buffered formalin (NBF) solution, which is typically used as a solution that is about 3.7% formalin (10% formaldehyde and 1% methanol).
- NVF neutral buffered formalin
- the term "slide” refers to any substrate (e.g., substrates made, in whole or in part, glass, quartz, plastic, silicon, etc.) of any suitable dimensions on which a biological specimen is placed for analysis, and more particularly to a "microscope slide” such as a standard 3 inch (7.62 cm) by 1 inch (2.54 cm) microscope slide or a standard 75 mm by 25 mm microscope slide.
- target refers to any molecule for which the presence, location and/or concentration is or can be determined.
- target molecules include proteins, epitopes, nucleic acid sequences, and haptens, such as haptens covalently bonded to proteins.
- Target molecules are typically detected using one or more conjugates of a specific binding molecule and a detectable label.
- the terms “unmask” or “unmasking” refer to retrieving antigens and/or improving the detection of amino acids, peptides, and proteins in a fixed tissue.
- the method includes contacting the sample with a retrieval agent and exposing the sample to UV radiation.
- the UV radiation is electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm.
- the UV radiation is electromagnetic radiation having a wavelength of between about 200 nm and about 400 nm.
- the UV radiation is electromagnetic radiation having a wavelength of between about 250 nm and about 400 nm.
- the UV radiation is applied to the fixed cell sample for a predetermined amount of time.
- the predetermined amount of time is a time period that is sufficient to unmask at least one antigen that was masked during the fixation process.
- the predetermined time can be established empirically by comparing a staining pattern for the at least one antigen (or target) before and after the exposure to the UV radiation.
- the staining pattern may be determined using a computer system, such as one coupled to an imaging device, the computer system comprising one or more processors and a memory, such as a non-transitory memory.
- UV radiation is introduced for a time period of about 2 hours or less. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 1 hour. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 45 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 3 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 15 minutes.
- UV radiation is introduced for a time period ranging from between about 5 minutes to about 20 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 5 minutes to about 15 minutes. In some embodiments, the time for UV irradiation depends on the frequency of the UV radiation, the angle of incidence from the UV radiation source to the sample, and/or the proximity of the UV radiation source to the sample.
- the UV radiation is introduced in pulses, i.e. where the UV radiation source is "on” for a period of time, followed by a period of time where the UV radiation source is "off.”
- the UV radiation source may be turned “on” for a period of time ranging from between about 0.5 seconds and about 60 seconds, followed by a period of time in which the UV radiation source is turned “off for a period of time ranging from between about 0.5 seconds to about 60 seconds.
- the retrieval agent comprises water and/or an aqueous buffer solution.
- the sample is also heated, such as to a temperature ranging from between about 30 C to about 150 C.
- the sample is heated for a predetermined amount of time (e.g. 10 seconds, 30 seconds, 60 seconds, etc.).
- the predetermined time of heating can coincide with a predetermined time of exposure to UV radiation, or could be shorter or longer time period, and can itself be established empirically by comparing a staining pattern for at least one antigen (or target) before and after the combination of UV treatment and heat exposure of the sample.
- Procedures for heating, such as by microwave heating, are described by Shan-Rong
- the fixed cell sample can be exposed to UV radiation and also be exposed to microwave radiation.
- the microwave radiation includes electromagnetic radiation having a wavelength ranging from between about 0.1 cm to about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 0.75 cm and about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 7.5 cm and about 15 cm. In some embodiments, the microwave radiation is applied to the sample for a predetermined amount of time.
- the exposure time for the microwave radiation can be sufficient to raise the temperature of the sample and/or the retrieval agent in contact with sample, or it could be applied in bursts so as to not significantly raise the temperature of the sample (e.g. pulses of microwave radiation of a predetermined number of seconds followed by pauses between pulses of a predetermined number of seconds).
- the predetermined time and pattern of exposure to the microwave radiation can be empirically established by comparing a staining pattern for at least one antigen (or target) before and after the particular combination of UV and microwave radiation exposure.
- a combination of UV exposure, microwave exposure (continuous or in bursts), and heating of the fixed cell sample can be applied to sufficiently unmask a particular antigen so that it can be detected in the fixed cell sample.
- a fixed cell sample can be exposed to ultrasound energy in addition to the UV radiation and/or microwave radiation for a predetermined amount of time.
- the time, length and intensity of any or all of the different electromagnetic energies or radiation can be established empirically by comparing a pattern of staining for a particular antigen (or target), as noted herein.
- the retrieval agent can be a buffer solution having a pH ranging from between about 5 and about 10. In particular embodiments, the retrieval agent can be a buffer solution having a pH ranging from between about 7 and about 9. In other particular embodiments, the retrieval agent can comprise a buffer solution having a pH ranging from between about 7.5 and about 11.
- buffers include citric acid, potassium dihydrogen phosphate, boric acid, diethyl barbituric acid, piperazine-N,N'-bis(2-ethanesulfonic acid), dimethylarsinic acid, 2-(N-morpholino)ethanesulfonic acid, tris(hydroxymethyl)methylamine (TRIS), 2-(N-morpholino)ethanesulfonic acid
- TPS N,N-bis(2-hydroxyethyl)glycine(Bicine), N- tris(hydroxymethyl)methylglycine
- Tricine 4-2-hydroxyethyl-l- piperazineethanesulfonic acid
- TES ⁇ [tris(hydroxymethyl)methyl] amino ⁇ ethanesulfonic acid
- the retrieval agent includes a tris based buffer with a slightly basic pH. In other embodiments, the retrieval agent includes about 100 mM Tris, the retrieval agent having a pH of between about 8 and about 10. In other embodiments, the retrieval agent includes about 0.05% citraconic anhydride. In other embodiments, the retrieval agent includes about 10 mM citrate with about 2 mM EDTA and with about 0.05% Tween 20, the retrieval agent having a pH of about 6.2. In other embodiments, the retrieval agent includes about 0.01M citrate buffer, the retrieval agent having a pH of about 6.0.
- the retrieval agent can include a reagent that reacts with any liberated fixative so as to prevent it from reacting again with the sample.
- a reagent that reacts with any liberated fixative include purpald or dimedone that are used to determine formaldehyde concentrations because they form very stable products.
- the retrieval agent can include a reagent that reacts in a reversible manner with free amino-groups of proteins and thus protects them from reaction with any available formaldehyde.
- a reagent that reacts in such a reversible manner is citraconic anhydride (CCA).
- the retrieval agent can include a chelator such as ethylenediammetetraacetic acid (EDTA).
- chelators include ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), EGTA/ AM (EGTA, Tetra(acetoxymethyl Ester)), (l,2-bis(o- aminophenoxy)ethane-N,N,N ⁇ N'-tetraacetic acid) (BAPTA), BAPTA/AM (EGTA Tetra(acetoxymethyl Ester)), 5 , 5 '-Dimethy 1-B APT A- AM ; l,2-Bis(2-amino-5- methylphenoxy) ethane (MAPTAM), N,N,N',N'-tetrakis(2-pyridylmethyl)ethane- 1,2-diamine (TPEN), citrate, or ionophores such as ethylenediammetetraace
- the retrieval agent can include an enzyme.
- an enzyme that can be included in the retrieval agent are a proteinase (such as trypsin, chymotrypsin, pepsin, or proteinase K), a nuclease, a glycanase, and a hyaluronidase.
- the retrieval agent can include a chaotropic agent.
- chaotropic agents include butanol, ethanol, a guanidinium salt (for example, guanidinium hydrochloride or guanidinium thiocyanate), lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, thiourea and urea.
- the retrieval agent can include a nucleophile, i.e. a chemical species that donates an electron pair to an electrophile.
- nucleophiles include ammonia, primary amines, secondary amines and tertiary amines.
- Other examples of nucleophiles include hydrazines, alcohols and halogenides.
- the retrieval agent can include a Lewis acid.
- Lewis acids include metal ions such as iron (III) ions, aluminium ions, magnesium ions or other electron-deficient compounds such as toluenesulfonic acid, boric acid, boron trifluoride, and tartaric acid.
- the retrieval agent can include a surfactant.
- surfactants are classified as anionic, cationic, or nonionic, depending on their mode of chemical action. In general, surfactants reduce interfacial tension between two liquids.
- An example of a surfactant is sodium dodecyl sulfate.
- nonionic surfactants include polyethylene glycol monohexadecyl ether, Cetostearyl alcohol, Cetyl alcohol, cocamide diethanolamine, cocamide monoethanolamine, Decyl glucoside, Octylphenoxypolyethoxyethanol, Polyethylene glycol monoisohexadecyl ether, Lauryl glucoside, Nonyl phenoxypolyethoxylethanol, 4-Nonylphenyl-polyethylene glycol, 1 -(4-Nonylphenyl)- 1, 4, 7, 10, 13, 16,19,22,25-nonaoxaheptacosan-27-ol, nonoxynols, Monolaurin, Octaethylene glycol monododecyl ether, Oleyl alcohol, Polyethylene-polypropylene glycol, Polyglycerol polyricinoleate, Polysorbates, Sorbitan monostearate.
- Sorbitan tristearate Stearyl alcohol; polyethylene glycol p- (l,l,3,3-tetramethylbutyl)-phenyl ether; Polyoxyethylene (20) sorbitan monooleate. octyl-, decyl, dodecyl-glucopyranoside, -maltoside or deoxycholic acid.
- Exemplary surfactants are sold under the names: Brij® 35, TWEEN®, TergitolTM, TritonTM, EcosurfTM, DowfaxTM, polysorbate 80TM, BigCHAP, Deoxy BigCHAP, IGEPAL®, Saponin, Thesit®, Nonidet®, Pluronic F-68, digitonin, deoxycholate, and the like. Particular disclosed working embodiments concern using surfactants selected from Brij® 35, TWEEN®, TergitolTM, TritonTM.
- the retrieval agent comprises deionized water, TRIS, and a chelator.
- the retrieval agent comprises deionized water, TRIS, and a chelator and has a pH ranging from between about 7 to about 9.5.
- the retrieval agent comprises deionized water, TRIS, a chelator, and a preservative.
- the retrieval agent is CC1, available from Ventana Medical Systems, Inc., Arlington, AZ, USA.
- the retrieval agent can include one, some or all of the different types of compounds listed above, and that the retrieval agent can be used in combination with UV radiation and one or more of microwave radiation, heat and ultrasound energy.
- the automated system includes a substrate holder configured to hold the substrate.
- a reagent dispenser is configured to dispense a retrieval agent onto the fixed cell sample, and a UV radiation source is configured to direct electromagnetic radiation toward the fixed cell sample.
- the automated system includes a controller that is configured to control the reagent dispenser to dispense the retrieval agent and to direct UV radiation toward the fixed cell sample in a predetermined sequence and for a predetermined amount of time.
- the source of UV radiation can be any known or future developed source of UV radiation, including, without limitation, an LED emitting a particular range of UV wavelengths or an array of LED lamps emitting a narrow spectrum of UV light or a broad spectrum of UV light, a mercury vapor lamp, a UV LED laser, or a xenon lamp, or any combination thereof.
- the source of UV radiation can be a source of one or more of UVA,
- the source of UV radiation can include wavelengths of between about 200 nm and about 400 nm.
- the automated system includes an enclosure surrounding one or more substrate holders, which enclosure can be pressurizable.
- the substrate holder can include a heating and/or cooling element (e.g. a conductive heating element or a Peltier heating and cooling element).
- the substrate holder can be automatically moveable under the direction of the controller into and out of the enclosure, such as through a door that can be sealed once the substrate holder is moved into the enclosure. Any of the slide holders disclosed in U.S. Patent Nos. 8,663,991;
- a substrate mover can be used to automatically place the substrate holding the fixed cell sample onto a stationary substrate holder kept inside the enclosure, such as through a sealable door mechanism.
- the automated system can include a source of microwave radiation and/or a source of ultrasound energy, such that microwaves or ultrasound are applied to the sample, such as at predetermined wavelengths or frequencies.
- the microwave radiation and or the ultrasound energy is applied for a predetermined period of time.
- microwave radiation or ultrasound energy is introduced for a time period ranging from between about 1 minute to about 60 minutes.
- microwave radiation or ultrasound energy is introduced for a time period ranging from between about 2 minutes to about 30 minutes.
- microwave radiation or ultrasound energy is introduced for a time period ranging from between about 3 minutes to about 15 minutes.
- microwave radiation or ultrasound energy is introduced for a time period ranging from between about 5 minutes to about 15 minutes.
- a larger system such as a specimen processing apparatus, might include other modules for performing other procedures on the substrate mounted biological samples, such as deparrafmization procedures, the application of antibodies and probes to the sample, drying, coverslipping, incubating and the like.
- a specimen processing apparatus may be utilized to apply a wide range of substances to the specimen.
- the substances include, without limitation, stains, probes, reagents, rinses, and/or conditioners (hereinafter collectively referred to as "stains").
- the substances can be fluids (e.g., gases, liquids, or gas/liquid mixtures), or the like.
- the fluids can be solvents (e.g., polar solvents, non-polar solvents, etc.), solutions (e.g., aqueous solutions or other types of solutions), or the like.
- Reagents can include, without limitation, stains, wetting agents, antibodies (e.g., monoclonal antibodies, polyclonal antibodies, etc.), antigen recovering fluids (e.g., aqueous- or non-aqueous-based antigen retrieval solutions, antigen recovering buffers, etc.), or the like.
- Probes can be an isolated nucleic acid or an isolated synthetic oligonucleotide, attached to a detectable label or reporter molecule. Labels can include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
- the specimen processing apparatus can be an automated apparatus, such as the BENCHMARK XT instrument and SYMPHONY instrument sold by Ventana Medical Systems, Inc. Ventana Medical Systems, Inc. is the assignee of a number of United States patents disclosing systems and methods for performing automated analyses, including U.S. Pat. Nos. 5,650,327, 5,654,200, 6,296,809,
- H&E stainers include the VENTANA SYMPHONY (individual slide stainer) and VENTANA HE 600 (individual slide stainer) series H&E stainers from Roche; the Dako CoverStainer
- the contactless mixer describes herein may be added to any of the aforementioned specimen processing systems.
- an apparatus for the treatment of a fixed sample that includes a chamber, which in some embodiments is pressurizable.
- the apparatus includes a removable rack configured to fit inside the chamber and to hold one or more substrates holding one or more fixed cells. Examples of suitable apparatuses include those described in United States Patent
- a UV light source (which can be any know or future developed source of UV light, such as noted herein) that is configured to operate within the chamber and direct UV light onto the one or more fixed cell samples.
- a UV light source (which can be any know or future developed source of UV light, such as noted herein) that is configured to operate within the chamber and direct UV light onto the one or more fixed cell samples.
- FIG. 1 studies were performed to determine the effectiveness of UV radiation in unmasking protein antigens using a Rayonet RPR- 200 Photochemical Reactor that is shown in panel A of FIG. 1.
- the interior of the UV reactor includes a number of UV lamps arranged around the periphery of the chamber. Microscope slides bearing tissue samples were placed into the container shown in panel C of FIG.
- FPET Formalin-fixed paraffin-embedded tissue
- a counter stain was applied. First one drop of hematoxylin was applied to the sample and allowed to incubate for 4 minutes under a coverslip. Next, a drop of bluing reagent was applied under a coverslip and allowed to incubate for an additional 4 min, and then coverslipped. [0057] As a pair of controls, an additional sample of tonsil tissue was subjected to a standardized, automated heat-induced antigen retrieval procedure on the followed by BCL-2 detection (BenchMark Ultra system, Ventana Medical Systems, Inc., Arlington, AZ, USA) and another sample was placed into the UV reactor for 2 hours, but covered with aluminum foil to prevent UV light from reaching the sample.
- BCL-2 detection BenchMark Ultra system, Ventana Medical Systems, Inc., Arlington, AZ, USA
- Control is shown which is stained according to a standardized heat-induced antigen retrieval procedure (i.e. heating of the sample or antigen retrieval agent), and where no UV light was applied to the sample.
- a standardized heat-induced antigen retrieval procedure i.e. heating of the sample or antigen retrieval agent
- UV light was applied to the sample.
- the brown staining of the BCL-2 protein is clearly evident.
- panel E of FIG. 2 is shown a micrograph of the control slide which received neither heat-induced antigen retrieval treatment according to the standardized procedures, nor any exposure to UV light. Little brown BCL-2 staining is evident in this control slide.
- panels B, C and D of FIG. 2 are micrographs of tonsil samples exposed to UV light for 2 hours, 1 hour and 30 minutes, respectively.
- FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods.
- the apparatus of FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods.
- the apparatus of FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods. The apparatus of FIG.
- enclosure 102 which may or may not be pressurizable
- UV source 104 that is positioned above substrate holder 108 on which microscope slide (substrate) 110 is placed and on top of which microscope slide 110 is fixed cell sample 112.
- reagent dispenser 106 which can be used to dispense a retrieval agent onto the fixed cell sample 112, and thereafter UV source 104 can direct UV radiation onto the fixed cell sample 112 for a predetermined amount of time.
- An example of a reagent dispenser is described in US Patent No. 8,790,596, the disclosure of which is hereby incorporated by reference herein in its entirety.
- a controller can be used to turn the UV light source on an off, and to actuate a pump, syringe, pipette (or the like) to dispense a retrieval agent onto the fixed cell sample 112.
- substrate holder 108 can include a heating or cooling mechanism (such as a conductive heater or a Peltier device).
- a heating or cooling mechanism such as a conductive heater or a Peltier device.
- An example of a slide heating device is described in US Patent Nos. 7,425,306 and 6,582,962, the disclosures of which are hereby incorporated by reference herein in their entireties.
- hot air or steam could be introduced into enclosure 102 to raise the temperature of the fixed cell sample 112. Where enclosure 102 is able to be pressurized, it is possible to raise the temperature within the enclosure without inducing boiling of the retrieval agent in contact with fixed cell sample 112.
- FIG. 5 shows a top view of a different embodiment of an apparatus 200 for carrying out the disclosed methods.
- apparatus 200 includes housing 202, which can include a lid (not show) and can be pressurizable.
- Removable rack 204 holds substrates 206a, 206b, 206c, 206d, 206e, 206f, 206g, and 206h, which although not shown explicitly, could hold fixed cell samples on either the surface facing the UV light source 208 or on the opposite surface.
- the apparatus of FIG. 5 can be used for manual treatment of fixed cell samples according to the disclosed methods, or for semi-automated methods (such as where the device includes a timer for turning UV light source 208 on an off after a pre-determined amount of time.
- UV light source 208 would advantageously be enclosed in a liquid-proof housing such that the interior space of the housing 202 could be filled with a retrieval agent solution. As discussed with respect to the system of FIG.
- the housing 202 could be pressurized to prevent boiling of the retrieval agent during the treatment process, particularly if the housing 202 also includes a heating element for raising the internal temperature of the apparatus.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Disclosed are methods and systems for unmasking protein antigens and nucleic acid targets in fixed cell samples using UV light. In some embodiments, UV light exposure is combined with other unmasking methods and agents to help ensure difficult to unmask molecular entities are reliably rendered detectable.
Description
METHOD AND SYSTEM FOR TREATING BIOLOGICAL SAMPLES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to and the benefit of the filing date of U.S. Provisional Patent Application No. 62/428,977, which was filed on December 1, 2016, the disclosure of which is hereby incorporated herein by reference in its entirety.
FIELD
[0002] The present disclosure relates to a method and system for unmasking protein antigens and nucleic acid targets from fixed biological samples, and more particularly, to a method and system for unmasking antigens and targets in fixed biological samples using ultraviolet light.
BACKGROUND
[0003] Fixation of tissue and cell samples is used to help ensure that the morphology of the sample and the spatial distribution of biomolecules is preserved and thus used for the basis of a diagnosis by a pathologist. As an adjunct to morphological indicators of disease, the presence of particular proteins and/or nucleic acid sequences can be used to further characterize a disease state and, in some instances, is used by an oncologist to direct therapy of the disease. However, fixation can also interfere with the detection of proteins and nucleic acids in a sample. As such, for immunohistochemical (IHC) procedures and in-situ hybridization (ISH) procedures, an unmasking step (also known as "antigen retrieval" or "target retrieval" for IHC and ISH, respectively) is often used make protein antigens or nucleic acid targets accessible to detection reagents such as antibodies or probes.
[0004] Fixation of samples is routinely accomplished using neutral- buffered formalin (NBF). It is believed that the formaldehyde in NBF preserves tissue and cell morphology by forming cross-links between reactive groups on proteins and nucleic acids in the sample, and these cross-links can lead to certain portions of the molecules being rendered undetectable. A variety of methods are used to reverse the effects of formalin fixation and provide access to antigens and
targets in fixed biological samples. None of these methods, however, is completely successful in all instances.
SUMMARY
[0005] The present disclosure provides methods and systems that facilitate the detection of protein and/or nucleic acid targets in a sample.
[0006] In one aspect of the present disclosure is a method for preparing a fixed cell sample for analysis, the method including contacting the sample with a retrieval agent and exposing the fixed cell sample to electromagnetic radiation, the electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm (UV radiation). In some embodiments, the electromagnetic radiation has a wavelength of between about 200 nm and about 400 nm. In some embodiments, the electromagnetic radiation has a wavelength of between about 250 nm and about 400nm. In some embodiments, the electromagnetic radiation includes one or more of UVA radiation (having a wavelength ranging from about 315nm to about 400 nm), UVB radiation (having a wavelength ranging from about 280nm to about 315 nm), and UVC radiation (having a wavelength ranging from about lOOnm to about280 nm).
[0007] In some embodiments, the retrieval agent is an antigen retrieval agent which includes one or more of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant. In some embodiments, the antigen retrieval agent includes at least two of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant. In some embodiments, the antigen retrieval agent includes at least three of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant. In some
embodiments, the antigen retrieval agent includes a buffer (e.g. TRIS) and has a pH ranging from about 7 to about 9.
[0008] In some embodiments, the method includes exposing the sample to one or more of heat, microwaves and ultrasound. In some embodiments, the sample is heated to between about 60 C and about 150 C. In some embodiments, when the sample is heating, it can be held under pressure to minimize evaporation of the antigen retrieval agent or mitigate or prevent the boiling of the antigen retrieval agent.
[0009] In another aspect of the present disclosure is an automated system for treating a fixed cell sample mounted on a substrate, the system including a substrate holder configured to hold the substrate, and a reagent dispenser configured to dispense a retrieval agent, e.g. an antigen retrieval agent, onto the fixed cell sample. In some embodiments, the system includes an electromagnetic radiation source configured to direct UV electromagnetic radiation toward the fixed cell sample. In some embodiments, UV electromagnetic radiation directed toward the fixed cell sample has wavelength of between about 200 nm and about 400 nm. In some embodiments, the system also includes a controller configured to control the dispenser and the electromagnetic radiation source to deliver the retrieval agent and direct the electromagnetic radiation (at a suitable wavelength or range of wavelengths) to the fixed cell sample mounted on the substrate. In some embodiments, the controller directs the operation of the dispenser and/or radiation source to operate according to a predetermined sequence and/or for a predetermined amount of time. In some embodiments, the controller optionally enables the direction of electromagnetic radiation toward the sample at a predetermined intensity or at a predetermined radiation flux. In some embodiments, the substrate holder includes a heating element. In some embodiments, the substrate holder is enclosed in a pressurizable chamber. In some embodiments, the system includes a source of microwave radiation that can be used to heat the sample and/or the retrieval agent. In some embodiments, the microwave radiation employed has a wavelength ranging from between about 7.5 cm to about
15 cm. In some embodiments, the substrate is glass. In some embodiments, the substrate is a microscope slide.
[0010] In another aspect of the present disclosure is an apparatus for the treatment of a fixed cell sample, the apparatus including a pressurizable chamber, a removable rack for mounting one or more substrates holding one or more fixed cell samples, and a UV light source configured to operate within the pressurizable chamber and direct UV light onto the one or more fixed cell samples. In a particular embodiment, a central UV light source is surrounded by a sample rack that fits around the periphery of the pressurizable chamber. BRIEF DESCRIPTION OF THE FIGURES
[0011] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings(s) will be provided by the Office upon request and payment of the necessary fee. [0012] Further features and advantages of disclosed system and method will become apparent in view of the Detailed Description that follows, and through reference to the accompanying figures in which:
[0013] FIG. 1 is a set of images showing the UV reactor apparatus used to expose the tissue samples shown in FIGS. 1 and 2 to UV light, where panel A is the outside of the UV reactor apparatus, panel B is a view from the top of the reactor showing the UV light sources arranged around the periphery, and panel C shows the tray in which slides were held at the bottom of the reactor apparatus.
[0014] FIG. 2 is set of micrographs illustrating the effect of ultraviolet treatment according to a disclosed method on FFPET tonsil tissue samples stained for the protein BCL-2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light
exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
[0015] FIG. 3 is a set of micrographs at a higher magnification that correspond to the micrographs of FIG. 2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
[0016] FIG. 4 is a schematic of an embodiment of the disclosed automated system for treating biological samples on microscope slides. [0017] FIG. 5 is a top-view schematic showing an embodiment of the disclosed apparatus for treatment of a fixed cell sample according to a disclosed method.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0018] As used herein, the singular terms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0019] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list
of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non- limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0020] The terms "comprising," "including," "having," and the like are used interchangeably and have the same meaning. Similarly, "comprises," "includes," "has," and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of "comprising" and is therefore interpreted to be an open term meaning "at least the following," and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, "a device having components a, b, and c" means that the device includes at least components a, b and c. Similarly, the phrase: "a method involving steps a, b, and c" means that the method includes at least steps a, b, and c. Moreover, while the steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary unless a particular order is clearly indicated by the context.
[0021] As used herein, the term "about" refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term "about" generally refers to a range of numerical values (e.g., +/— 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term "about" may include numerical values that are rounded to the nearest significant figure.
[0022] As used herein, the term "substantially" means the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. In some embodiments, "substantially" means within about 20%. In some embodiments, "substantially" means within about 15%. In some embodiments, "substantially" means within about 10%. In some embodiments,
"substantially" means within about 5%.
[0023] As used herein, the term "antigen" refers to a compound, composition, or substance that may be specifically bound by the products of specific humoral or cellular immunity, such as an antibody molecule or T-cell receptor. Antigens can be any type of molecule including, for example, haptens, simple intermediary metabolites, sugars (e.g., oligosaccharides), lipids, and hormones as well as macromolecules such as complex carbohydrates (e.g., polysaccharides), phospholipids, nucleic acids and proteins.
[0024] As used herein the term "biological sample" refers to any sample including a biomolecule (such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof) that is obtained from any organism including viruses. Other examples of organisms include mammals (such as humans; veterinary animals like cats, dogs, horses, cattle, and swine; and laboratory animals like mice, rats and primates), insects, annelids, arachnids, marsupials, reptiles, amphibians, bacteria, and fungi. Biological samples include tissue samples (such as tissue sections and needle biopsies of tissue), cell samples (such as cytological smears such as Pap smears or blood smears or samples of cells obtained by microdissection), or cell fractions, fragments or organelles (such as obtained by lysing cells and separating their components by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (for example, obtained by a surgical biopsy or a needle biopsy), nipple aspirates, cerumen, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample. In certain embodiments, the term "biological sample" as used herein refers
to a sample (such as a homogenized or liquefied sample) prepared from a tumor or a portion thereof obtained from a subject.
[0025] As used herein, the term "cell sample" refers to a biological sample comprising cells or a morphological portion thereof, which cells can be individual cells or can be arranged together in a tissue structure. In one embodiment, the cell sample is a collection of cells (such as blood or cervical cells) placed onto a microscope slide. In another embodiment, the cell sample is a frozen tissue section placed on a microscope slide. In yet another embodiment, the cell sample is a formalin-fixed paraffin-embedded tissue sample (FFPET sample), prepared by first fixing a collection of cells or a piece of tissue using formalin, which is then processed using know techniques to dehydrate the sample, clear the sample and impregnate the sample in a block of paraffin (or other materials) such that it can be sliced into thin sections that are placed onto a microscope slide for treatment and analysis. [0026] As used herein the term "fixed cell sample" refers to a biological sample that has been treated to help preserve the morphological and/or biochemical features of the cells as they existed before the biological sample was obtained from the organism or alternatively before the sample was obtained from a culture of material originally obtained from a biological sample (e.g. a culture of bacteria present in mucus or pus). A fixed cell sample can, for example, be prepared by contacting the sample with an aldehyde fixative such as formaldehyde or glutaraldehyde. A fixed cell sample can be prepared by contacting the sample with an alcohol-based fixative such as one including methanol, ethanol or acetic acid. Alternatively, a fixed cell sample can be prepared by contacting the sample with an oxidizing agent such as osmium tetraoxide or potassium permanganate, or a fixed cell sample can be prepared using a metallic based fixative such as mercuric chloride or picric acid. In a particular embodiment, a fixed cell sample is prepared by contacting a biological sample comprising cells with a neutral buffered formalin (NBF) solution, which is typically used as a solution that is about 3.7% formalin (10% formaldehyde and 1% methanol).
[0027] As used herein, the term "slide" refers to any substrate (e.g., substrates made, in whole or in part, glass, quartz, plastic, silicon, etc.) of any suitable dimensions on which a biological specimen is placed for analysis, and more particularly to a "microscope slide" such as a standard 3 inch (7.62 cm) by 1 inch (2.54 cm) microscope slide or a standard 75 mm by 25 mm microscope slide.
Examples of biological specimens that can be placed on a slide include, without limitation, a cytological smear, a thin tissue section (such as from a biopsy), and an array of biological specimens, for example a tissue array, a cellular array, a DNA array, an RNA array, a protein array, or any combination thereof. [0028] As used herein, the term "target" refers to any molecule for which the presence, location and/or concentration is or can be determined. Examples of target molecules include proteins, epitopes, nucleic acid sequences, and haptens, such as haptens covalently bonded to proteins. Target molecules are typically detected using one or more conjugates of a specific binding molecule and a detectable label.
[0029] As used herein, the terms "unmask" or "unmasking" refer to retrieving antigens and/or improving the detection of amino acids, peptides, and proteins in a fixed tissue.
[0030] In one embodiment, is a method of preparing a fixed cell sample for analysis. In some embodiments, the method includes contacting the sample with a retrieval agent and exposing the sample to UV radiation. In some embodiments, the UV radiation is electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm. In other embodiments, the UV radiation is electromagnetic radiation having a wavelength of between about 200 nm and about 400 nm. In other embodiments, the UV radiation is electromagnetic radiation having a wavelength of between about 250 nm and about 400 nm. In some embodiments, the UV radiation is applied to the fixed cell sample for a predetermined amount of time. In some embodiments, the predetermined amount of time is a time period that is sufficient to unmask at least one antigen that was masked during the fixation process. In some embodiments, the predetermined time
can be established empirically by comparing a staining pattern for the at least one antigen (or target) before and after the exposure to the UV radiation. The staining pattern may be determined using a computer system, such as one coupled to an imaging device, the computer system comprising one or more processors and a memory, such as a non-transitory memory.
[0031] In some embodiments, UV radiation is introduced for a time period of about 2 hours or less. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 1 hour. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 45 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 3 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 15 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 5 minutes to about 20 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 5 minutes to about 15 minutes. In some embodiments, the time for UV irradiation depends on the frequency of the UV radiation, the angle of incidence from the UV radiation source to the sample, and/or the proximity of the UV radiation source to the sample.
[0032] In some embodiments, the UV radiation is introduced in pulses, i.e. where the UV radiation source is "on" for a period of time, followed by a period of time where the UV radiation source is "off." For example, the UV radiation source may be turned "on" for a period of time ranging from between about 0.5 seconds and about 60 seconds, followed by a period of time in which the UV radiation source is turned "off for a period of time ranging from between about 0.5 seconds to about 60 seconds.
[0033] In some embodiments, the retrieval agent comprises water and/or an aqueous buffer solution. In some embodiments, the sample is also heated, such as to a temperature ranging from between about 30 C to about 150 C. In some embodiments, the sample is heated for a predetermined amount of time (e.g. 10 seconds, 30 seconds, 60 seconds, etc.). In some embodiments, the predetermined time of heating can coincide with a predetermined time of exposure to UV radiation, or could be shorter or longer time period, and can itself be established empirically by comparing a staining pattern for at least one antigen (or target) before and after the combination of UV treatment and heat exposure of the sample. Procedures for heating, such as by microwave heating, are described by Shan-Rong
Shi, Antigen Retrieval Immunohistochemistry: Review and Future Prospects in Research and Diagnosis over Two Decades, Journal of Histochemistry & Cytochemistry 59(1) 13-32, the disclosure of which is hereby incorporated by reference herein in its entirety. Another procedure for heat-induced antigen retrieval is described in US Patent No. 9,506,928, the disclosure of which is hereby incorporated by reference herein in its entirety. For example, the '928 Patent describes heating from about 70°C to about 95°C for about 30 minutes to facilitate the unmasking or retrieval of chemical epitopes.
[0034] Another procedure for heat-induced antigen retrieval procedure was disclosed by Ding et al., "Water Bath and Pressure Cooker Antigen Retrieval in
Immunohistochemistry: A Comparative Study," Appl Immunohistochem Mol Morphol, Volume 22, Number 3, March 2014. There, the authors disclosed placing dewaxed and rehydrated slides into heat-resistant plastic slide racks and where the racks were immersed in a glass or stainless-steel breaker filled with 300mL of an antigen retrieval solution (e.g. buffer (0.01M citrate buffer, pH 6.0)). The breaker was then placed in a pressure cooker filled with 1500mL of distilled water or antigen retrieval solution. The cooker was finally placed on a conventional electric stove (400 or 1200 W) or an induction cooker (rated at 1200 W), covered with an unlocked lid, and heated to a boil. The slides were immersed in the boiling solution and reheated to a boil.
[0035] In other embodiments, the fixed cell sample can be exposed to UV radiation and also be exposed to microwave radiation. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength ranging from between about 0.1 cm to about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 0.75 cm and about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 7.5 cm and about 15 cm. In some embodiments, the microwave radiation is applied to the sample for a predetermined amount of time. In some embodiments, the exposure time for the microwave radiation can be sufficient to raise the temperature of the sample and/or the retrieval agent in contact with sample, or it could be applied in bursts so as to not significantly raise the temperature of the sample (e.g. pulses of microwave radiation of a predetermined number of seconds followed by pauses between pulses of a predetermined number of seconds). The predetermined time and pattern of exposure to the microwave radiation can be empirically established by comparing a staining pattern for at least one antigen (or target) before and after the particular combination of UV and microwave radiation exposure. In still other embodiments, a combination of UV exposure, microwave exposure (continuous or in bursts), and heating of the fixed cell sample can be applied to sufficiently unmask a particular antigen so that it can be detected in the fixed cell sample.
[0036] In still other embodiments, a fixed cell sample can be exposed to ultrasound energy in addition to the UV radiation and/or microwave radiation for a predetermined amount of time. The time, length and intensity of any or all of the different electromagnetic energies or radiation can be established empirically by comparing a pattern of staining for a particular antigen (or target), as noted herein.
[0037] In particular embodiments, the retrieval agent can be a buffer solution having a pH ranging from between about 5 and about 10. In particular embodiments, the retrieval agent can be a buffer solution having a pH ranging from between about 7 and about 9. In other particular embodiments, the retrieval agent
can comprise a buffer solution having a pH ranging from between about 7.5 and about 11. Examples of buffers include citric acid, potassium dihydrogen phosphate, boric acid, diethyl barbituric acid, piperazine-N,N'-bis(2-ethanesulfonic acid), dimethylarsinic acid, 2-(N-morpholino)ethanesulfonic acid, tris(hydroxymethyl)methylamine (TRIS), 2-(N-morpholino)ethanesulfonic acid
(TAPS), N,N-bis(2-hydroxyethyl)glycine(Bicine), N- tris(hydroxymethyl)methylglycine (Tricine), 4-2-hydroxyethyl-l- piperazineethanesulfonic acid (HEPES), 2-
{[tris(hydroxymethyl)methyl] amino }ethanesulfonic acid (TES), and combinations thereof.
[0038] In some embodiments, the retrieval agent includes a tris based buffer with a slightly basic pH. In other embodiments, the retrieval agent includes about 100 mM Tris, the retrieval agent having a pH of between about 8 and about 10. In other embodiments, the retrieval agent includes about 0.05% citraconic anhydride. In other embodiments, the retrieval agent includes about 10 mM citrate with about 2 mM EDTA and with about 0.05% Tween 20, the retrieval agent having a pH of about 6.2. In other embodiments, the retrieval agent includes about 0.01M citrate buffer, the retrieval agent having a pH of about 6.0.
[0039] In some embodiments, the retrieval agent can include a reagent that reacts with any liberated fixative so as to prevent it from reacting again with the sample. Examples a reagent that reacts with any liberated fixative include purpald or dimedone that are used to determine formaldehyde concentrations because they form very stable products. Alternatively, or in addition, the retrieval agent can include a reagent that reacts in a reversible manner with free amino-groups of proteins and thus protects them from reaction with any available formaldehyde. An example of a reagent that reacts in such a reversible manner is citraconic anhydride (CCA).
[0040] In other particular embodiments, the retrieval agent can include a chelator such as ethylenediammetetraacetic acid (EDTA). Additional examples of chelators include ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N'-tetraacetic
acid (EGTA), EGTA/ AM (EGTA, Tetra(acetoxymethyl Ester)), (l,2-bis(o- aminophenoxy)ethane-N,N,N\N'-tetraacetic acid) (BAPTA), BAPTA/AM (EGTA Tetra(acetoxymethyl Ester)), 5 , 5 '-Dimethy 1-B APT A- AM ; l,2-Bis(2-amino-5- methylphenoxy) ethane (MAPTAM), N,N,N',N'-tetrakis(2-pyridylmethyl)ethane- 1,2-diamine (TPEN), citrate, or ionophores such as ionomycin or calcimycin, or any combination or mixtures thereof.
[0041] In further embodiments, the retrieval agent can include an enzyme. Examples of an enzyme that can be included in the retrieval agent are a proteinase (such as trypsin, chymotrypsin, pepsin, or proteinase K), a nuclease, a glycanase, and a hyaluronidase.
[0042] In still further embodiments, the retrieval agent can include a chaotropic agent. Examples of chaotropic agents include butanol, ethanol, a guanidinium salt (for example, guanidinium hydrochloride or guanidinium thiocyanate), lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, thiourea and urea.
[0043] In even further embodiments, the retrieval agent can include a nucleophile, i.e. a chemical species that donates an electron pair to an electrophile. Examples of nucleophiles include ammonia, primary amines, secondary amines and tertiary amines. Other examples of nucleophiles include hydrazines, alcohols and halogenides.
[0044] In other embodiments, the retrieval agent can include a Lewis acid. Examples of Lewis acids include metal ions such as iron (III) ions, aluminium ions, magnesium ions or other electron-deficient compounds such as toluenesulfonic acid, boric acid, boron trifluoride, and tartaric acid. [0045] In other embodiments, the retrieval agent can include a surfactant.
As used herein, "surfactants" are classified as anionic, cationic, or nonionic, depending on their mode of chemical action. In general, surfactants reduce interfacial tension between two liquids. An example of a surfactant is sodium
dodecyl sulfate. Examples of suitable nonionic surfactants include polyethylene glycol monohexadecyl ether, Cetostearyl alcohol, Cetyl alcohol, cocamide diethanolamine, cocamide monoethanolamine, Decyl glucoside, Octylphenoxypolyethoxyethanol, Polyethylene glycol monoisohexadecyl ether, Lauryl glucoside, Nonyl phenoxypolyethoxylethanol, 4-Nonylphenyl-polyethylene glycol, 1 -(4-Nonylphenyl)- 1, 4, 7, 10, 13, 16,19,22,25-nonaoxaheptacosan-27-ol, nonoxynols, Monolaurin, Octaethylene glycol monododecyl ether, Oleyl alcohol, Polyethylene-polypropylene glycol, Polyglycerol polyricinoleate, Polysorbates, Sorbitan monostearate. Sorbitan tristearate; Stearyl alcohol; polyethylene glycol p- (l,l,3,3-tetramethylbutyl)-phenyl ether; Polyoxyethylene (20) sorbitan monooleate. octyl-, decyl, dodecyl-glucopyranoside, -maltoside or deoxycholic acid. Exemplary surfactants are sold under the names: Brij® 35, TWEEN®, Tergitol™, Triton™, Ecosurf™, Dowfax™, polysorbate 80™, BigCHAP, Deoxy BigCHAP, IGEPAL®, Saponin, Thesit®, Nonidet®, Pluronic F-68, digitonin, deoxycholate, and the like. Particular disclosed working embodiments concern using surfactants selected from Brij® 35, TWEEN®, Tergitol™, Triton™.
[0046] In some embodiments, the retrieval agent comprises deionized water, TRIS, and a chelator. In some embodiments, the retrieval agent comprises deionized water, TRIS, and a chelator and has a pH ranging from between about 7 to about 9.5. In some embodiments, the retrieval agent comprises deionized water, TRIS, a chelator, and a preservative. In some embodiments, the retrieval agent is CC1, available from Ventana Medical Systems, Inc., Tucson, AZ, USA.
[0047] It is to be understood that in various embodiments the retrieval agent can include one, some or all of the different types of compounds listed above, and that the retrieval agent can be used in combination with UV radiation and one or more of microwave radiation, heat and ultrasound energy.
[0048] Also disclosed is an automated system for the treatment of a fixed cell sample mounted on a substrate. In some embodiments, the automated system includes a substrate holder configured to hold the substrate. A reagent dispenser is configured to dispense a retrieval agent onto the fixed cell sample, and a UV
radiation source is configured to direct electromagnetic radiation toward the fixed cell sample. In some embodiments, the automated system includes a controller that is configured to control the reagent dispenser to dispense the retrieval agent and to direct UV radiation toward the fixed cell sample in a predetermined sequence and for a predetermined amount of time. The source of UV radiation can be any known or future developed source of UV radiation, including, without limitation, an LED emitting a particular range of UV wavelengths or an array of LED lamps emitting a narrow spectrum of UV light or a broad spectrum of UV light, a mercury vapor lamp, a UV LED laser, or a xenon lamp, or any combination thereof. In particular embodiments, the source of UV radiation can be a source of one or more of UVA,
UVB and UVC radiation. In other particular embodiments, the source of UV radiation can include wavelengths of between about 200 nm and about 400 nm.
[0049] In some embodiments, the automated system includes an enclosure surrounding one or more substrate holders, which enclosure can be pressurizable. In even more particular embodiments, the substrate holder can include a heating and/or cooling element (e.g. a conductive heating element or a Peltier heating and cooling element). In other embodiments, the substrate holder can be automatically moveable under the direction of the controller into and out of the enclosure, such as through a door that can be sealed once the substrate holder is moved into the enclosure. Any of the slide holders disclosed in U.S. Patent Nos. 8,663,991;
8,048,373; and 7,468,161; and U.S. Patent Publication No. 2016/0282239 (the disclosures of each are hereby incorporated by reference herein in their entireties) may be adapted for use in the present disclosure. Alternatively, a substrate mover can be used to automatically place the substrate holding the fixed cell sample onto a stationary substrate holder kept inside the enclosure, such as through a sealable door mechanism.
[0050] In other particular embodiments, the automated system can include a source of microwave radiation and/or a source of ultrasound energy, such that microwaves or ultrasound are applied to the sample, such as at predetermined wavelengths or frequencies. In some embodiments, the microwave radiation and or
the ultrasound energy is applied for a predetermined period of time. In some embodiments, microwave radiation or ultrasound energy is introduced for a time period ranging from between about 1 minute to about 60 minutes. In some embodiments, microwave radiation or ultrasound energy is introduced for a time period ranging from between about 2 minutes to about 30 minutes. In some embodiments, microwave radiation or ultrasound energy is introduced for a time period ranging from between about 3 minutes to about 15 minutes. In some embodiments, microwave radiation or ultrasound energy is introduced for a time period ranging from between about 5 minutes to about 15 minutes. [0051] It is to be understood that the disclosed apparatus for the treatment of a fixed cell sample could be one module in a much larger system for treating biological samples held on substrates. A larger system, such as a specimen processing apparatus, might include other modules for performing other procedures on the substrate mounted biological samples, such as deparrafmization procedures, the application of antibodies and probes to the sample, drying, coverslipping, incubating and the like. For example, a specimen processing apparatus may be utilized to apply a wide range of substances to the specimen. The substances include, without limitation, stains, probes, reagents, rinses, and/or conditioners (hereinafter collectively referred to as "stains"). The substances can be fluids (e.g., gases, liquids, or gas/liquid mixtures), or the like. The fluids can be solvents (e.g., polar solvents, non-polar solvents, etc.), solutions (e.g., aqueous solutions or other types of solutions), or the like. Reagents can include, without limitation, stains, wetting agents, antibodies (e.g., monoclonal antibodies, polyclonal antibodies, etc.), antigen recovering fluids (e.g., aqueous- or non-aqueous-based antigen retrieval solutions, antigen recovering buffers, etc.), or the like. Probes can be an isolated nucleic acid or an isolated synthetic oligonucleotide, attached to a detectable label or reporter molecule. Labels can include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
[0052] The specimen processing apparatus can be an automated apparatus, such as the BENCHMARK XT instrument and SYMPHONY instrument sold by Ventana Medical Systems, Inc. Ventana Medical Systems, Inc. is the assignee of a number of United States patents disclosing systems and methods for performing automated analyses, including U.S. Pat. Nos. 5,650,327, 5,654,200, 6,296,809,
6,352,861, 6,827,901 and 6,943,029, and U.S. Published Patent Application Nos. 20030211630 and 20040052685, each of which is incorporated herein by reference in its entirety. Examples of commercially available H&E stainers include the VENTANA SYMPHONY (individual slide stainer) and VENTANA HE 600 (individual slide stainer) series H&E stainers from Roche; the Dako CoverStainer
(batch stainer) from Agilent Technologies; the Leica ST4020 Small Linear Stainer (batch stainer), Leica ST5020 Multistainer (batch stainer), and the Leica ST5010 Autostainer XL series (batch stainer) H&E stainers from Leica Biosystems Nussloch GmbH. The contactless mixer describes herein may be added to any of the aforementioned specimen processing systems.
[0053] Also disclosed is an apparatus for the treatment of a fixed sample that includes a chamber, which in some embodiments is pressurizable. In some embodiments, the apparatus includes a removable rack configured to fit inside the chamber and to hold one or more substrates holding one or more fixed cells. Examples of suitable apparatuses include those described in United States Patent
Nos. 6,534,008, 8,361,388, 8,377,377 and related family members, the disclosures of which are hereby incorporated by reference herein in their entireties.
[0054] Also included in the apparatus is a UV light source (which can be any know or future developed source of UV light, such as noted herein) that is configured to operate within the chamber and direct UV light onto the one or more fixed cell samples.
[0055] Referring now to FIG. 1, studies were performed to determine the effectiveness of UV radiation in unmasking protein antigens using a Rayonet RPR- 200 Photochemical Reactor that is shown in panel A of FIG. 1. As shown in panel B of FIG. 1, the interior of the UV reactor includes a number of UV lamps arranged around the periphery of the chamber. Microscope slides bearing tissue samples were placed into the container shown in panel C of FIG. 1 and covered with a thin layer of cell conditioning solution 1 (CC-1, Ventana Medical Systems, Inc., Tucson, AZ, USA), then exposed to UV light for a predetermined amount of time. Formalin-fixed paraffin-embedded tissue (FFPET) sections of tonsil tissue were first deparaffinized using a standard method performed on a Sakura Tissue-Tek
Prisma AID Automated Slide Stainer, removed and placed into the tray of panel C of FIG. 1 for UV treatment.
[0056] Following UV treatment for a predetermined amount of time (2 hours, 1 hour or 30 minutes), the slides were removed from the UV reactor and were subjected to a procedure for detection of the protein BCL-2 according to a standard protocol on a BenchMark Ultra system (Ventana Medical Systems, Inc., Tucson, AZ, USA). This procedure included application of a peroxidase inhibitor, followed by application of a primary antibody specific for the BCL-2 protein (SP66, Ventana Medical Systems, Inc., Tucson, AZ, USA) and allowed to incubate under a coverslip for 16 minutes. DAB detection (OptiView DAB, Ventana Medical Systems, Inc., Tucson, AZ, USA) of the bound BCL-2 antibodies was then performed. Following the antibody treatment and detection, a counter stain was applied. First one drop of hematoxylin was applied to the sample and allowed to incubate for 4 minutes under a coverslip. Next, a drop of bluing reagent was applied under a coverslip and allowed to incubate for an additional 4 min, and then coverslipped.
[0057] As a pair of controls, an additional sample of tonsil tissue was subjected to a standardized, automated heat-induced antigen retrieval procedure on the followed by BCL-2 detection (BenchMark Ultra system, Ventana Medical Systems, Inc., Tucson, AZ, USA) and another sample was placed into the UV reactor for 2 hours, but covered with aluminum foil to prevent UV light from reaching the sample. All samples where then examined microscopically for staining of the BCL-2 protein, which is a known tonsil protein that requires antigen retrieval to be made visible in tonsil tissue. The results of these studies are shown in FIGS. 2 and 3. [0058] In panel A of FIG 2, a positive control slide (labeled OptiView
Control) is shown which is stained according to a standardized heat-induced antigen retrieval procedure (i.e. heating of the sample or antigen retrieval agent), and where no UV light was applied to the sample. In this panel, the brown staining of the BCL-2 protein is clearly evident. [0059] In panel E of FIG. 2 is shown a micrograph of the control slide which received neither heat-induced antigen retrieval treatment according to the standardized procedures, nor any exposure to UV light. Little brown BCL-2 staining is evident in this control slide.
[0060] In contrast, panels B, C and D of FIG. 2 are micrographs of tonsil samples exposed to UV light for 2 hours, 1 hour and 30 minutes, respectively.
Since the negative control slide was also held in the reactor for the maximum time of 2 hours, it is clear that any antigen retrieval as evidence by BCL-2 staining was due to exposure to UV light and not any heating effect due to the lamps in the UV reactor. A comparison of panels B, C and D clearly demonstrates that the increase in the amount of BCL-2 staining correlates with the amount of time the samples were subjected to UV radiation. FIG. 3 shows micrographs corresponding to those of FIG 2, only at higher magnifications.
[0061] FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods. The apparatus of FIG. 4 includes, in this embodiment, enclosure 102 (which may or may not be pressurizable) and UV source 104 that is positioned above substrate holder 108 on which microscope slide (substrate) 110 is placed and on top of which microscope slide 110 is fixed cell sample 112. Also shown is reagent dispenser 106 which can be used to dispense a retrieval agent onto the fixed cell sample 112, and thereafter UV source 104 can direct UV radiation onto the fixed cell sample 112 for a predetermined amount of time. An example of a reagent dispenser is described in US Patent No. 8,790,596, the disclosure of which is hereby incorporated by reference herein in its entirety. A controller (not shown) can be used to turn the UV light source on an off, and to actuate a pump, syringe, pipette (or the like) to dispense a retrieval agent onto the fixed cell sample 112. [0062] In some embodiments, substrate holder 108 can include a heating or cooling mechanism (such as a conductive heater or a Peltier device). An example of a slide heating device is described in US Patent Nos. 7,425,306 and 6,582,962, the disclosures of which are hereby incorporated by reference herein in their entireties. Alternatively, hot air or steam could be introduced into enclosure 102 to raise the temperature of the fixed cell sample 112. Where enclosure 102 is able to be pressurized, it is possible to raise the temperature within the enclosure without inducing boiling of the retrieval agent in contact with fixed cell sample 112.
[0063] FIG. 5 shows a top view of a different embodiment of an apparatus 200 for carrying out the disclosed methods. In this embodiment, apparatus 200 includes housing 202, which can include a lid (not show) and can be pressurizable.
Removable rack 204 holds substrates 206a, 206b, 206c, 206d, 206e, 206f, 206g, and 206h, which although not shown explicitly, could hold fixed cell samples on either the surface facing the UV light source 208 or on the opposite surface. In various embodiments, the apparatus of FIG. 5 can be used for manual treatment of fixed cell samples according to the disclosed methods, or for semi-automated
methods (such as where the device includes a timer for turning UV light source 208 on an off after a pre-determined amount of time. In practice, UV light source 208 would advantageously be enclosed in a liquid-proof housing such that the interior space of the housing 202 could be filled with a retrieval agent solution. As discussed with respect to the system of FIG. 4, the housing 202 could be pressurized to prevent boiling of the retrieval agent during the treatment process, particularly if the housing 202 also includes a heating element for raising the internal temperature of the apparatus. Thus, the advantages of both heat-induced and UV-induced antigen retrieval/target retrieval can be realized.
[0064] Although described with respect to particular embodiments, it should be clear that the disclosed methods and systems can be modified without departing from the scope as defined by the claims that follow.
Claims
1. A method for preparing a fixed cell sample for analysis, comprising:
a) contacting the sample with a retrieval agent, and;
b) exposing the fixed cell sample to electromagnetic radiation, the
electromagnetic radiation having a wavelength ranging from between about 10 nm and about 400 nm.
2. The method of claim 1, wherein the retrieval agent comprises water.
3. The method of any of the preceding claims, further comprising exposing the fixed cell sample to a temperature of between about 30°C and about 150° C
4. The method of any of the preceding claims, further comprising exposing the fixed cell sample to additional electromagnetic radiation, the additional electromagnetic radiation having a wavelength between about 0.1 cm and about 100 cm.
5. The method of claim 4, wherein the additional electromagnetic radiation has a wavelength of between about 0.75 cm and about 100 cm.
6. The method of claim 5, wherein the additional electromagnetic radiation has a wavelength between about 7.5 cm and about 15 cm.
7. The method of any of the preceding claims, wherein the electromagnetic
radiation has a wavelength ranging from between about 200 nm and about 400 nm.
8. The method of claim 7, wherein the electromagnetic radiation has a wavelength ranging from between about 250 nm and about 400 nm.
9. The method of any of the preceding claims, wherein the retrieval agent comprises tris(hydroxymethyl)aminomethane and has a pH ranging from between about 6 and about 8.
10. The method of any of the preceding claims, wherein the retrieval agent
comprises an enzyme.
11. The method of any of the preceding claims, wherein the retrieval agent
comprises a chaotropic agent.
12. The method of any of the preceding claims, wherein the retrieval agent
comprises a nucleophilic agent.
13. The method of any of the preceding claims, wherein the fixed cell sample is a formalin-fixed cell sample, wherein there the method further comprises passing ultrasound through the sample.
14. The method of any of the preceding claims, wherein the fixed cell sample comprises an aldehyde-fixed cell sample.
15. The method of claim 14, wherein the aldehyde-fixed cell sample comprises a formalin-fixed cell sample.
16. The method of any of the preceding claims, wherein the retrieval agent
comprises at least two of a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron- deficient compound, and a surfactant.
17. The method of any of the preceding claims, wherein the retrieval agent consists essentially of a buffer.
18. The method of any of any of the preceding claims, wherein the retrieval agent consists essentially of water and a salt.
19. An automated system for treatment of a fixed cell sample mounted on a substrate, comprising:
a) a substrate holder configured to hold the substrate;
b) a reagent dispenser configured to dispense a retrieval agent onto the fixed cell sample;
c) an electromagnetic radiation source configured to direct electromagnetic radiation toward the fixed cell sample, the electromagnetic radiation having a wavelength of between about 200 nm and about 400 nm; and
d) a controller configured to control the dispenser and the electromagnetic radiation source to deliver the retrieval agent and impinge the
electromagnetic radiation onto the fixed cell sample mounted on the substrate in a predetermined sequence and for a predetermined amount of time.
20. The automated system of claim 19, wherein the substrate holder further
comprises a heating element.
21. The automated system of claim 19, further comprising an additional source of electromagnetic radiation configured to direct additional electromagnetic radiation toward the fixed cell sample, wherein the additional electromagnetic radiation has a wavelength of between about 7.5 cm and about 15 cm.
22. The automated system of claim 19, wherein the substrate holder is enclosed in a pressurizable chamber.
23. An apparatus for treatment of a fixed cell sample, comprising:
a) a pressurizable chamber;
a removable rack for mounting one or more substrates holding one or more fixed cell samples; and
a UV light source configured to operate within the pressurizable chamber and direct UV light onto the one or more fixed cell samples.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662428977P | 2016-12-01 | 2016-12-01 | |
US62/428,977 | 2016-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018100017A1 true WO2018100017A1 (en) | 2018-06-07 |
Family
ID=60812018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/080894 WO2018100017A1 (en) | 2016-12-01 | 2017-11-30 | Method and system for treating biological samples |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018100017A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016492A (en) * | 2019-04-15 | 2019-07-16 | 吉林金域医学检验所有限公司 | A kind of Gram's stain |
CN110361348A (en) * | 2019-08-22 | 2019-10-22 | 赵云红 | A kind of total nitrogen detection system and its total nitrogen detection method for water quality detection |
CN113785184A (en) * | 2019-05-14 | 2021-12-10 | 文塔纳医疗***公司 | System comprising a biological sample processing chamber |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007031874A2 (en) * | 2005-07-01 | 2007-03-22 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
US20100028978A1 (en) * | 2005-05-24 | 2010-02-04 | Angros Lee H | In situ heat induced antigen recovery and staining apparatus and method |
US20150148243A1 (en) * | 2013-11-22 | 2015-05-28 | Samsung Electronics Co., Ltd. | Method for reversible fixation or selective lysis of cell using photocleavable polymer |
-
2017
- 2017-11-30 WO PCT/EP2017/080894 patent/WO2018100017A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100028978A1 (en) * | 2005-05-24 | 2010-02-04 | Angros Lee H | In situ heat induced antigen recovery and staining apparatus and method |
WO2007031874A2 (en) * | 2005-07-01 | 2007-03-22 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
US20150148243A1 (en) * | 2013-11-22 | 2015-05-28 | Samsung Electronics Co., Ltd. | Method for reversible fixation or selective lysis of cell using photocleavable polymer |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016492A (en) * | 2019-04-15 | 2019-07-16 | 吉林金域医学检验所有限公司 | A kind of Gram's stain |
CN113785184A (en) * | 2019-05-14 | 2021-12-10 | 文塔纳医疗***公司 | System comprising a biological sample processing chamber |
CN110361348A (en) * | 2019-08-22 | 2019-10-22 | 赵云红 | A kind of total nitrogen detection system and its total nitrogen detection method for water quality detection |
CN110361348B (en) * | 2019-08-22 | 2021-12-03 | 海南聚兴环保科技有限公司 | Total nitrogen detection system for water quality detection and total nitrogen detection method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1337831T3 (en) | REMOVAL OF BIOLOGICAL SAMPLING AND CELL CONDITIONING MEDIA ON AUTOMATIC DYING INSTRUMENTS | |
US20140273088A1 (en) | Method, apparatus and system for staining of biological samples | |
JP2004525366A (en) | Automated immunohistochemistry and in situ hybridization assay formulations | |
US11376600B2 (en) | Non-contact, on-slide fluid mixing | |
WO2018100017A1 (en) | Method and system for treating biological samples | |
DK2300799T3 (en) | Process for the histo chemical processing and use of a composition for histo chemical processing | |
CA2543043A1 (en) | Simplified tissue processing | |
WO2009085574A2 (en) | Microwave antigen retrieval in non-aqueous solvents | |
WO2001044784A1 (en) | Microwave unit and system for tissue processing | |
EP2467695B1 (en) | Apparatus and method for accelerated tissue infiltration by means of microwave excitation | |
JP2003526086A (en) | Removal of embedding media from biological samples and cell conditioning in automated staining equipment | |
EP2122324B1 (en) | Horizontal antigen retrieval | |
US20080064085A1 (en) | Microwave-assisted heating and processing techniques | |
EP3729047A2 (en) | Eosin staining techniques | |
AU2018391801B2 (en) | Phenol-free acid-fast staining composition and use thereof | |
Sheat et al. | Duplex in situ hybridization of virus nucleic acids in plant tissues using RNAscope® | |
AU2014208296B2 (en) | Compositions comprising nanomaterials and method for using such compositions for histochemical processes | |
US20230407379A1 (en) | Electric field aided sample preparation | |
Itaya et al. | Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity | |
Cintrón et al. | Automated Immunohistochemistry Assay for the Detection of Napsin-A in Formalin-Fixed Paraffin-Embedded Tissues from Lung Tumors | |
Shi et al. | Use of monoclonal antibodies in immunohistochemistry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17821481 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17821481 Country of ref document: EP Kind code of ref document: A1 |